Regulation of STAT1 Signaling in Human Pancreatic β-Cells by the Lysine Deacetylase HDAC6: A New Therapeutic Opportunity in Type 1 Diabetes?
Diabetes · 2024
DOI: 10.2337/db24-0008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Kaiyven Afi Leslie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Islet Biology Group (IBEx), Exeter Centre of Excellence in Diabetes (EXCEED), Department of Clinical and Biomedical Sciences, University of Exeter, E…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, STAT1 Transcription Factor, Histone Deacetylases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Diabetes UK.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes arises from the selective destruction of pancreatic β-cells by autoimmune mechanisms, and intracellular pathways driven by Janus kinase (JAK)–mediated phosphorylation of STAT isoforms (especially STAT1 and STAT2) are implicated as mediators of β-cell demise. Despite this, the molecular mechanisms that regulate JAK-STAT signaling in β-cells during the autoimmune attack remain only partially disclosed, and the factors acting to antagonize proinflammatory STAT1 signaling are uncertain. We have recently implicated signal regulatory protein α (SIRPα) in promoting β-cell viability in the face of ongoing islet autoimmunity and have now revealed that this protein controls the availability of a cytosolic lysine deacetylase, HDAC6, whose activity regulates the phosphorylation and activation of STAT1. We provide evidence that STAT1 serves as a substrate for HDAC6 in β-cells and that sequestration of HDAC6 by SIRPα in response to anti-inflammatory cytokines (e.g., IL-13) leads to increased STAT1 acetylation. This then impairs the ability of STAT1 to promote gene transcription in response to proinflammatory cytokines, including interferon-γ. We further found that SIRPα is lost from the β-cells of subjects with recent-onset type 1 diabetes under conditions when HDAC6 is retained and STAT1 levels are increased. On this basis, we report a previously unrecognized role for cytokine-induced regulation of STAT1 acetylation in the control of β-cell viability and propose that targeted inhibition of HDAC6 activity may represent a novel therapeutic modality to promote β-cell viability in the face of active islet autoimmunity. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Islet Biology Group (IBEx), Exeter Centre of Excellence in Diabetes (EXCEED), Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, U.K.
ORCID-Profile: Sarah J Richardson, Noel G Morgan
Förderung
- Diabetes UK
Zitieren
APA
Leslie, K. A., Lekka, C., Richardson, S. J., Russell, M. A., & Morgan, N. G. (2024). Regulation of STAT1 Signaling in Human Pancreatic β-Cells by the Lysine Deacetylase HDAC6: A New Therapeutic Opportunity in Type 1 Diabetes?. Diabetes. https://doi.org/10.2337/db24-0008
Vancouver
Leslie KA, Lekka C, Richardson SJ, Russell MA, Morgan NG. Regulation of STAT1 Signaling in Human Pancreatic β-Cells by the Lysine Deacetylase HDAC6: A New Therapeutic Opportunity in Type 1 Diabetes?. Diabetes. 2024. doi:10.2337/db24-0008
BibTeX
@article{Leslie2024,
author = {Leslie, Kaiyven Afi and Lekka, Christiana and Richardson, Sarah J and Russell, Mark A and Morgan, Noel G},
title = {Regulation of STAT1 Signaling in Human Pancreatic β-Cells by the Lysine Deacetylase HDAC6: A New Therapeutic Opportunity in Type 1 Diabetes?},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db24-0008}
}
EUVIMED